Gastrointestinal neuroendocrine tumors: A role for targeted therapies?

Endocrine-Related Cancer

Volumn 14, Issue 2, 2007, Pages 207-219

  Kulke, Matthew H ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOPEPTIN; BEVACIZUMAB; CHLOROZOTOCIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; GEFITINIB; GEMCITABINE; IMATINIB; LUTETIUM 177; MAMMALIAN TARGET OF RAPAMYCIN; OCTREOTIDE; PACLITAXEL; PEGINTERFERON ALPHA2B; PENTETREOTIDE IN 111; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE;

ABDOMINAL PAIN; ANTINEOPLASTIC ACTIVITY; ARTIFICIAL EMBOLISM; BONE MARROW SUPPRESSION; CARCINOID; CARCINOID SYNDROME; CHOLELITHIASIS; CLINICAL STUDY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG INHIBITION; DRUG MEGADOSE; ENDOCRINE TUMOR; FATIGUE; GASTROINTESTINAL TUMOR; GRANULOCYTOPENIA; HEMATOLOGIC DISEASE; HEMATOLOGY; HORMONE RELEASE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INJECTION SITE IRRITATION; LIVER METASTASIS; LOW DRUG DOSE; MONOTHERAPY; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; NEUROPATHY; NEUTROPENIA; OPPORTUNISTIC INFECTION; PANCREAS TUMOR; PHEOCHROMOCYTOMA; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; REMISSION; REVIEW; SIDE EFFECT; STEATORRHEA; THROMBOCYTOPENIA; THYROID FUNCTION;

GASTROINTESTINAL NEOPLASMS; HUMANS; NEUROENDOCRINE TUMORS;

EID: 34547730261     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-06-0061     Document Type: Review

References (99)

1. Ajani JA, Carrasco CH, Charnsangavej C, Samaan NA, Levin B & Wallace S 1988 Islet cell tumors metastatic to the liver: effective palliation by sequential hepatic artery embolization. Annals of Internal Medicine 108 340-344.
2. Alsina AE, Bartus S, Hull D, Rosson R & Schweizer RT 1990 Liver transplant for metastatic neuroendocrine tumor. Journal of Clinical Gastroenterology 12 533-537.
3. Ambs S, Bennett WP, Merriam WG, Ogunfusika MO, Oser SM, Khan MA, Jones RT & Harris CC 1998 Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53. British Journal of Cancer 78 233-239.
4. Ansell S, Pitot H, Burch P, Kvols L, Mahoney M & Rubin J 2001 A phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer 91 1543-1548.
5. Anthony L, Woltering E, Espenan G, Cronin M, Maloney T & McCarthy K 2002 Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Seminars in Nuclear Medicine 32 123-132.
6. Berber E, Flesher N & Siperstein AE 2002 Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World Journal of Surgery 26 985-990.
7. Brown KT, Koh BY, Brady LA, Getrajdman GI, Susman J, Fong Y & Blumgart LH 1999 Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. Journal of Vascular and Interventional Radiology 10 397-403.
8. Bukowski R, Johnson K, Peterson R, Stephens R, Rivkin S, Neilan B & Costanzi J 1987 A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. Cancer 60 2891-2895.
9. Bukowski R, Tangen C, Peterson R, Taylor S, Rinehart J, Eyre H, Rivkin S, Fleming T & Macdonald J 1994 Phase 11 trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group study. Cancer 73 1505-1508.
10. Buscombe J, Caplin M & Hilson A 2003 Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors. Journal of Nuclear Medicine 44 1-6.
11. Chaudhry A, Papanicolaou V, Oberg K, Heldin CH & Funa K 1992 Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system. Cancer Research 52 1006-1012.
12. Chaudhry A, Funa K & Oberg K 1993 Expression of growth factor peptides and their receptors in neuroendocrine tumors of the digestive system. Acta Oncologica 32 107-114.
13. Chaudhry A, Oberg K, Gobi A, Heldin CH & Funa K 1994 Expression of transforming growth factors beta 1, beta 2, beta 3 in neuroendocrine tumors of the digestive system. Anticancer Research 14 2085-2091.
14. Cheng P & Saltz L 1999 Failure to confirm major objective antitumor activity ofr streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 86 944-948.
15. Christofori G, Naik P & Hanahan D 1995 Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. Molecular Endocrinology 9 1760-1770.
16. Chung MH, Pisegna J, Spirt M, Giuliano AE, Ye W, Ramming KP & Bilchik AJ 2001 Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver. Surgery 130 954-962.
17. Diamandidou E, Ajani JA, Yang DJ, Chuang VP, Brown CA, Carrasco HC, Lawrence DD & Wallace S 1998 Two-phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors. AJR. American Journal of Roentgenology 170 339-344.
18. Dominguez S, Denys A, Madeira I, Hammel P, Vilgrain V, Menu Y, Bernades P & Ruszniewski P 2000 Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumours. European Journal of Gastroenterology and Hepatology 12 151-157.
19. Drougas JG, Anthony LB, Blair TK, Lopez RR, Wright JK Jr, Chapman WC, Webb L, Mazer M, Meranze S & Pinson CW 1998 Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors. American Journal of Surgery 175 408-412.
20. Ducreux M, Ruszniewski P, Chayvialle JA, Blumberg J, Cloarec D, Michel H, Raymond JM, Dupas JL, Gouerou H, Jian R et al. 2000 The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. American Journal of Gastroenterology 95 3276-3281.
21. Duran I, Kortmansky J, Singh D, Hirte H, Kocha W, Goss G, Le L, Oza A, Nicklee T, Ho J et al. 2006 A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. British Journal of Cancer 95 1148-1154.
22. Engstrom P, Lavin P, Moertel C, Folsch E & Douglass H 1984 Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. Journal of Clinical Oncology 2 1255-1259.
23. Eriksson BK, Larsson EG, Skogseid BM, Lofberg AM, Lorelius LE & Oberg KE 1998 Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 83 2293-2301.
24. Faiss S, Rath U, Mansmann U, Caird D, Clemens N, Riecken EO & Wiedenmann B 1999 Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors. Digestion 60 469-476.
25. Faiss S, Pape U, Bohmig M, Dorffel Y, Mansmann U, Golder W, Rieck E & Wiedenmann B 2003 Prospective, randomized multicenter trial on the antiproliferative effect of lanreotide, interferon alpha, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors-the International Lanreotide and Interferon Alpha Study Group. Journal of Clinical Oncology 21 2689-2696.
26. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G et al. 2006 Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. Journal of Clinical Oncology 24 25-35.
27. Feldman J & O'Dirisio T 1986 Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors. American Journal of Medicine 81 41-48.
28. Florman S, Toure B, Kim L, Gondolesi G, Roayaie S, Krieger N, Fishbein T, Emre S, Miller C & Schwartz M 2004 Liver transplantation for neuroendocrine tumors. Journal of Gastrointestinal Surgery 8 208-212.
29. Frank M, Klose KJ, Wied M, Ishaque N, Schade-Brittinger C & Arnold R 1999 Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. American Journal of Gastroenterology 94 1381-1387.
30. Givi B, Pommier SJ, Thompson AK, Diggs BS & Pommier RF 2006 Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival. Surgery 140 891-897 (discussion 897-898).
31. Gulec SA, Mountcastle TS, Frey D, Cundiff JD, Mathews E, Anthony L, O'Leary JP & Boudreaux JP 2002 Cytoreductive surgery in patients with advanced-stage carcinoid tumors. American Surgeon 68 667-671 (discussion 671-662).
32. Gupta S, Yao J, Ahrar K, Wallace M, Morello F, Madoff D, Murthy R, Hicks M & Ajani J 2003 Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the MD Anderson experience. Cancer Journal 9 261-267.
33. Hellman P, Ladjevardi S, Skogseid B, Akerstrom G & Elvin A 2002 Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World Journal of Surgery 26 1052-1056.
34. Hobday T, Holen K, Donehower R, Camoriano J, Kim G, Picus J, Philip P, Lloyd R, Mahoney M & Erlichman C 2006 A phase II trial of gefitinib in patients with progressive metastatic neuroendocrine tumors: a phase II consortium study. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings 24 A4043.
35. Hopfner M, Sutter AP, Gerst B, Zeitz M & Scherubl H 2003 A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839). British Journal of Cancer 89 1766-1775.
36. Hopfner M, Baradari V, Huether A, Schorl C & Scherubl H 2006 The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours. Endocrine-Related Cancer 13 135-149.
37. Janson E & Oberg K 1993 Long term management of the carcinoid syndrome: treatment with octreotide alone and in combination with alpha-interferon. Acta Oncologica 32 225-229.
38. Janson E, Holmberg L, Stridsberg M, Eriksson B, Theodorsson E, Wilander E & Oberg K 1997 Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Annals of Oncology 8 685-690.
39. DeJong M, Valkema R, Jamar F, Kvols L, Kwekkeboom D, Breeman W, Bakker W, Smith C, Pauwels S & Krenning E 2002 Somatostatin-receptor targeted radionucleotide therapy of tumors: preclinical and clinical findings. Seminars in Nuclear Medicine 32 133-140.
40. Kaltsas G, Korbonits M, Heintz E, Mukherjee J, Jenkins P, Chew S, Reznek R, Monson J, Besser G, Foley R et al. 2001 Comparison of somatostatin analog and metaiodobenzylguanidine radionuclites in the diagnosis and localization of advanced neuroendocrine tumors. Journal of Clinical Endocrinology and Metabolism 86 895-902.
41. Kelsen D, Fiore J, Heelan R, Cheng E & Magill G 1987 Phase II trial of etoposide in APUD tumors. Cancer Treatment Reports 71 305-307.
42. Knox CD, Feurer ID, Wise PE, Lamps LW, Kelly Wright J, Chart RS, Lee Gorden D & Wright Pinson C 2004 Survival and functional quality of life after resection for hepatic carcinoid metastasis. Journal of Gastrointestinal Surgery 8 653-659.
43. Kolby L, Persson G, Franzen S & Ahren B 2003 Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. British Journal of Surgery 90 687-693.
44. Kouvaraki M, Ajani J, Hoff P, Wolff R, Evans D, Lozano R & Yao J 2004 Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. Journal of Clinical Oncology 22 4762-4771.
45. Krishnamurthy S & Dayal Y 1997 Immunohistochemical expression of transforming growth factor alpha and epidermal growth factor receptor in gastrointestinal carcinoids. American Journal of Surgical Pathology 21 327-333.
46. Kulke M, Fuchs C, Stuart K, Ryan D, Enzinger P, Vincitore M, Berg D, Clark J & Mayer R 2004a Phase II study of docetaxel in patients with metastatic carcinoid tumors. Cancer Investigation 22 353-359.
47. Kulke MH, Kim H, Clark JW, Enzinger PC, Lynch TJ, Morgan JA, Vincitore M, Michelini A & Fuchs CS 2004b A phase II trial of gemcitabine for metastatic neuroendocrine tumors. Cancer 101 934-939.
48. Kulke M, Lenz H, Meropol N, Posey J, Ryan D, Picus J, Bergsland E, Stuart K, Baum C & Fuchs C 2005 Results of a phase II study with sunitinib malate (SU11248) in patients with advanced neuroendocrine tumours ECCO. European Journal of Cancer Supplement 3 204.
49. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A & Fuchs CS 2006 Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. Journal of Clinical Oncology 24 401-406.
50. Kvols L, Moertel C, O'Connell M, Schutt A, Rubin J & Hahn R 1986 Treatment of the malignant carcinoid syndrome: evaluation of a long-acting somatostatin analog. New England Journal of Medicine 315 663-666.
51. Kvols LK, Brown ML, O'Connor MK, Hung JC, Hayostek RJ, Reubi JC & Lamberts SW 1993 Evaluation of a radiolabeled somatostatin analog (I-123 octreotide) in the detection and localization of carcinoid and islet cell tumors. Radiology 187 129-133.
52. Kwekkeboom D, Bakker W, Kam B, Teunissen J, Kooij P, Herder Wd, Feelders R, Eijck Cv, Jong Md, Srinivasan A et al. 2003 Treatment of patients with gastro-enteropancreatic (GEP) tumours with the novel radiolabelled somatostatin analouge [177Lu-DOTA(0), Try3] octreotate. European Journal of Nuclear Medicine and Molecular Imaging 30 417-422.
53. Kwekkeboom D, Teunissen J, Bakker W, Kooij P, Herder Wd, Feelders R, vanEijck C, Esser J, Kam B & Krenning E 2005 Radiolabled somatostatin analog [177Lu-DOTA0,Try3] octreotate in patients with endocrine gastroenteropancreatic tumors. Journal of Clinical Oncology 23 2754-2762.
54. Lamberts S, Bakker W, Reubi J & Krenning E 1990 Somatostatin receptor imaging in the localization of endocrine tumors. New England Journal of Medicine 323 1246-1249.
55. Lang H, Oldhafer K, Weimann A, Schlitt H, Scheumann G, Flemming P, Ringe B & Pichlmayr R 1997 Liver transplantation for metastatic neuroendocrine tumors. Annals of Surgery 225 347-354.
56. Lankat-Buttgereit B, Horsch D, Barth P, Arnold R, Blocker S & Goke R 2005 Effects of the tyrosine kinase inhibitor imatinib on neuroendocrine tumor cell growth. Digestion 71 131-140.
57. Loewe C, Schindl M, Cejna M, Niederle B, Lammer J & Thurnher S 2003 Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results. AJR. American Journal of Roentgenology 180 1379-1384.
58. McCarthy K, Woltering E, Espenen G, Cronin M, Maloney T & Anthony L 1998 In situ radiotherapy with 111InPentreotide: initial observations and future directions. Cancer Journal from Scientific American 4 94-102.
59. McCollum AD, Kulke MH, Ryan DP, Clark JW, Shulman LN, Mayer RJ, Bartel S & Fuchs CS 2004 Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. American Journal of Clinical Oncology 27 485-488.
60. Meyers M, Anthony L, McCarthy K, Drouant G, Maloney T, Espanan G & Woltering E 2000 High-dose indium 111In pentetreotide radiotherapy for metastatic atypical carcinoid tumor. Southern Medical Journal 93 809-811.
61. Moertel CG & Hanley JA 1979 Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clinical Trials 2 327-334.
62. Moertel C, Lefkopoulo M, Lipsitz S, Hahn R & Klaassen D 1992 Streptozocin-doxorubicin, stretpozocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. New England Journal of Medicine 326 519-523.
63. Moertel C, Johnson C, McKusick M, Martin J, Nagorney D, Kvols L, Rubin J & Kunselman S 1994 The management of patients with advanced carcinoid tumors and islet cell carcinoma. Annals of Internal Medicine 120 302-309.
64. Musunuru S, Chen H, Rajpal S, Stephani N, McDermott JC, Holen K, Rikkers LF & Weber SM 2006 Metastatic neuroendocrine hepatic tumors: resection improves survival. Archives of Surgery 141 1000-1004 (discussion 1005).
65. Nilsson O, Wangberg B, Kolby L, Schultz GS & Ahlman H 1995 Expression of transforming growth factor alpha and its receptor in human neuroendocrine tumours. International Journal of Cancer 60 645-651.
66. Oberg K & Eriksson B 1991 The role of interferons in the management of carcinoid tumors. Acta Oncologica 30 519-522.
67. Oberg K, Funa K & Alm G 1983 Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. New England Journal of Medicine 309 129-133.
68. Oberg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G, Ruszniewski P, Woltering EA & Wiedenmann B 2004 Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Annals of Oncology 15 966-973.
69. Osborne DA, Zervos EE, Strosberg J, Boe BA, Malafa M, Rosemurgy AS, Yeatman TJ, Carey L, Duhaine L & Kvols LK 2006 Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Annals of Surgical Oncology 13 572-581.
70. O'Toole D, Ducreux M, Bommelaer G, Wemeau JL, Bouche O, Catus F, Blumberg J & Ruszniewski P 2000 Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 88 770-776.
71. Paganelli G, Bodei L, Handkiewicz DJ, Junak D, Rocca P, Papi S, Lopera-Sierra M, Gatti M, Chinol M, Bartolomei M et al. 2002 90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies. Biopolymers 66 393-398.
72. Ramanathan RK, Cnaan A, Hahn RG, Carbone PP & Haller DG 2001 Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Annals of Oncology 12 1139-1143.
73. La Rosa S, Uccella S, Finzi G, Albarello L, Sessa F & Capella C 2003 Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features. Human Pathology 34 18-27.
74. Rubin J, Ajani J, Schirmer W, Venook A, Bukowski R, Pommier R, Dandona P & Anthony L 1999 Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. Journal of Clinical Oncology 17 600-606.
75. Ruszniewski P, Rougier P, Roche A, Legmann P, Sibert A, Hochlaf S, Ychou M & Mignon M 1993 Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. Cancer 71 2624-2630.
76. Saltz L, Trochanowski B, Buckley M, Heffernan B, Niedzwiecki D, Tao Y & Kelsen D 1993 Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer 72 244-248.
77. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM & Que FG 2003 Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. Journal of the American College of Surgeons 197 29-37.
78. Seregni E, Ferrari L, Bajetta E, Martinetti A & Bombardieri E 2001 Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Annals of Oncology 12 S69-S72.
79. Smolewski P 2006 Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs 17 487-494.
80. Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, Baig G, Goddard C, Gibson NW, Slack JA et al. 1987 Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5- tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Research 47 5846-5852.
81. Stivanello M, Berruti A, Torta M, Termine A, Tampellini M, Gorzegno G, Angeli A & Dogliotti L 2001 Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience. Annals of Oncology 12 S73-S77.
82. Sugimoto E, Lorelius L, Eriksson B & Oberg K 1995 Midgut carcinoid tumors: CT appearance. Radiologica 36 367-371.
83. Sun W, Lipsitz S, Catalano P, Malliard J, Haler D & Group ECO 2005 Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study El281. Journal of Clinical Oncology 23 4897-4904.
84. Terris B, Scoazec J & Rubbia L 1998 Expression of vascular endothelial growth factor in digestive neuroendocrine tumors. Histopathology 32 133-138.
85. Thorson A, Biorck G, Bjorkman G & Waldenstrom J 1954 Malignant carcinoid of the small intestine with metastases to the liver, valvular disease on the right side of the heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and an unusual type of cyanosis. American Heart Journal 47 795-817.
86. Tomassetti P, Migliori M, Simoni P, Casadei R, De Iasio R, Corinaldesi R & Gullo L 2001 Diagnostic value of plasma chromogranin A in neuroendocrine tumours. European Journal of Gastroenterology and Hepatology 13 55-58.
87. Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD & Pitt HA 2005 Neuroendocrine hepatic metastases: does aggressive management improve survival? Annals of Surgery 241 776-783 (discussion 783-775).
88. Le Treut YP, Delpero JR, Dousset B, Cherqui D, Segol P, Mantion G, Hannoun L, Benhamou G, Launois B, Boillot O et al. 1997 Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report. Annals of Surgery 225 355-364.
89. Valimaki M, Jarvinen H, Salmela P, Sane T, Sjoblom S & Pelkonen R 1991 Is the treatment of metastatic carcinoid tumor with interferon not as successful as suggested? Cancer 67 547-549.
90. Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, Barone R, Walrand S, Kooij PP, Bakker WH et al. 2005 Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. Journal of Nuclear Medicine 46 83S-91S.
91. Vignot S, Faivre S, Aguirre D & Raymond E 2005 mTOR-targeted therapy of cancer with rapamycin derivatives. Annals of Oncology 16 525-537.
92. van Vilsteren FG, Baskin-Bey ES, Nagorney DM, Sanderson SO, Kremers WK, Rosen CB, Gores GJ & Hobday TJ 2006 Liver transplantation for gastroenteropancreatic neuroendocrine cancers: defining selection criteria to improve survival. Liver Transplantation 12 448-456.
93. Virgolini I, Traub T, Novotny C, Leimer M, Fuger B, Li SR, Patri P, Pangerl T, Angelberger P, Raderer M et al. 2002 Experience with indium-111 and yttrium-90-labeled somatostatin analogs. Current Pharmaceutical Design 8 1781-1807.
94. Waldherr C, Pless M, Maecke H, Schumacher T, Crazzolara A, Nitzsche E, Haldemann A & Mueller-Brand J 2002 Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC. Journal of Nuclear Medicine 43 610-616.
95. Woodard P, Feldman J, Paine S & Baker M 1995 Midgut carcinoid tumors: CT findings and biochemical profiles. Journal of Computer Assisted Tomography 19 400-405.
96. Wymenga AN, Eriksson B, Salmela PI, Jacobsen MB, Van Cutsem EJ, Fiasse RH, Valimaki MJ, Renstrup J, de Vries EG & Oberg KE 1999 Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. Journal of Clinical Oncology 17 1111.
97. Yao J, NG C, Hoff P, Phan K, Hess H, Chen X, Wang J, Abbruzzese J & Ajani A 2005 Improved progression-free survival and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumab (abstract). Journal of Clinical Oncology Supplement 23.
98. Yao J, Phan T, Chang D, Jacobs C, Mares J, Rashid A & Meric-Bernstam F 2006 Phase II study of RAD001 (everolimus) and depot octreotide (Sandostatin LAR) in patients with advanced low grade neuroendocrine carcinoma. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings 24 A4042.
99. Yao JC, Zhang JX, Rashid A, Yeung SC, Szklaruk J, Hess K, Xie K, Ellis L, Abbruzzese JL & Ajani JA 2007 Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clinical Cancer Research 13 234-240.